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Assessment of hemopoietic progenitor cells in cell culture correlates with 
cytogenetic analysis of patients with chronic myeloid leukemia. 
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Somatic mutation of the pluripotent hematopoietic ceil known as BCR-ABL 
is associated with chronic myeloid leukemia (CML). Such rearrangement often 
induces formation of the Philadelphia chromosome also known as 9,22 trans-
location that is common to all patients with actively proliferating cancerous 
hematopoietic cells of myeloid lineages and in some B-lymphocytes. Total of 
12 CML patients were studied at the age of 20 to 46 years that received treatment 
with TKl family drugs such as Imatinib (Novartis co.) between 18 and 36 months. 
Four out of 12 were not treated prior to start of experiments. Patients had under-
gone hematological and cytogenetic analysis for the Philadelphia chromosome 
and molecular investigations with determination ofthe p210 transcript (BCR-ABL) 
by the PCR methodology. In parallel, clinical tests were accompanied by in vitro 
investigations in semisolid agar cultures. Colony-forming activity ofthe GM, 
BFU-E, CFU-GMM was determined. Thus, culture methods along with cytogenetic 
and molecular methods may form an adequate approach for determination ofthe 
success ofthe therapy and patient monitoring for CML All patients investigated 
have shown a positive correlation between cytogenetic methods and in vitro 
cultures. Full hematological remission and normalization ofthe CFU activity in 
culture was achieved in 4 non-pretreated patients, who were treated immediately 
after the diagnosis. The rest 8 patients obtained major cytogenetic response, 
two of them had the progression of disease 2 years after treatment. Therefore, 
treatment with TKI family drugs has a strong positive effect on the recovery 
of normal hematopoiesis in patients with CML. 
